Acute respiratory distress syndrome



pulmonary critical care :: Article Creator

Pulmonary, Allergy And Critical Care Medicine

The UAB Division of Pulmonary, Allergy and Critical Care Medicine is an integral part of one of the nation's largest health systems. Nationally known for our compassionate care, cutting-edge research, and comprehensive training programs, we're dedicated to delivering the most advanced care.


Agustin, Yamamoto Join FHP Health Center

Dr. Michael Agustin and Dr. Michele Therese L. Yamamoto recently joined the FHP Health Center.

Agustin, FCCP FAPSR, holds board certifications in Pulmonary Medicine Critical Care and Internal Medicine by the American board of Internal Medicine.

"With his breadth of experience, dedication to patient care, and leadership skills, Dr. Agustin is a valuable addition to FHP's healthcare team," Rose Grino, RN, health care delivery administrator at FHP Health Center, said in a press release. "He is committed to providing high-quality medical services to our patients and the community."

Yamamoto is a board-certified Infectious Disease and Internal Medicine physician by the American Board of Internal Medicine.

"The FHP Health Center welcomes Dr. Yamamoto to the team," Grino said. "Dr. Yamamoto is a valuable addition to our healthcare community. Her dedication to providing compassionate and comprehensive medical treatment will enhance our patient care."

Agustin

Agustin, who earned his Doctor of Medicine degree at the University of Santo Tomas Faculty of Medicine and Surgery in the Philippines, completed his Internal Medicine residency at the Memorial Hospital of Rhode Island Alpert School of Medicine Brown University. He was awarded Intern of the Year 2011 and Resident of the Year 2013.

His specialized training includes a Pulmonary and Critical Care Fellowship Program at St. Elizabeth Medical Center, Tufts University in Boston, Massachusetts.

Agustin joined Guam Regional Medical City after his fellowship in 2016. He served as the chairman of the Department of Medicine for GRMC, section head of Pulmonary Medicine, Intensive Care Unit director and head of the Ethics Committee before being the interim chief medical officer at GRMC.

He then focused on establishing the Lung Center for Guam and co-founded GLID Center, Guam. He is the first recipient of GRMC's Physician of the Year award 2021.

Agustin is an active member of professional societies.

He holds a license to practice medicine in Rhode Island, Massachusetts, Guam and the Philippines. He also holds affiliations with the Philippine Medical Association, as well as the Makati Medical Society.

Agustin will also join Makati Life Medical Center in Makati, Philippines, where he will establish a satellite pulmonary clinic for Guam patients by Fall 2024.

Yamamoto

Yamamoto completed her Doctor of Medicine degree also from the University of Santo Tomas Faculty of Medicine and Surgery with cum laude honors, and completed her Internal Medicine residency at the Memorial Hospital of Rhode Island Alpert School of Medicine Brown University. She was also awarded Intern of the Year 2012 and the Elise Coletta Award for Teaching Year 2014.

Her specialized training includes an Infectious Diseases and Immunology Fellowship from the University of Massachusetts Medical School in Worcester, Massachusetts.

She joined GRMC in 2016 after her fellowship and has been the section head of Infectious Disease. She holds administrative roles as the head of Infection Control and Antimicrobial Stewardship.

Together with Agustin, Yamamoto co-founded GLID, Guam, and together they have published multiple case reports and presented cases to international conferences. She was GRMC's Physician of the Year 2022.

She's also active in various professional societies, and holds a license to practice medicine in Rhode Island, Massachusetts, Guam and the Philippines. She also holds affiliations with the Philippine Medical Association as well as the Makati Medical Society.

Yamamoto will also open a satellite Infectious Disease clinic for Guam and Micronesia patients at the Makati Life Medical Center, Philippines.


COPD Care: Assessing The Role Of PICk-UP Program Beyond Pulmonary Rehabilitation

Photo Credit: KatarzynaBialasiewicz

The following is a summary of "Beyond Pulmonary Rehabilitation: can the PICk-UP program fill the gap? A Randomized Trial in COPD," published in the May 2024 issue of Pulmonology by Rebelo et al.

Pulmonary rehabilitation (PR) is pivotal in managing COPD, yet sustaining its benefits remains a challenge. This study aimed to evaluate the efficacy and effectiveness of a personalized community-based physical activity program that aims to prolong PR benefits among individuals with COPD.

Conducted as a multicenter, assessor-blinded, randomized controlled trial, the study enrolled patients with COPD who completed a 12-week PR program. Participants were randomized to either a six-month personalized community-based physical activity program (experimental group) or standard care (control group). Primary outcomes included daily time spent in moderate to vigorous physical activities, steps per day and scores from the brief physical activity assessment tool. Secondary outcomes encompassed sedentary behavior, functional status, peripheral muscle strength, balance, symptoms, emotional state, health-related quality of life, exacerbations, and healthcare utilization. Assessments were conducted immediately post-PR and at three- and six-month intervals. Efficacy and effectiveness were analyzed using intention-to-treat and per-protocol approaches with linear mixed models.

The study included 61 participants (experimental group: n = 32; control group: n = 29), with balanced baseline characteristics (mean age 69.6 ± 8.5 years, 84% male, FEV1 57.1 ± 16.7% predicted). At the six-month follow-up, significant improvements (P < 0.05) favoring the experimental group were observed in all physical activity outcomes and in the one-minute sit-to-stand test. No significant differences between groups were noted in other secondary outcomes.

The community-based physical activity program effectively enhanced physical activity levels and sit-to-stand performance among patients with COPD six months post-PR. However, it did not confer additional benefits across other measured outcomes. These findings underscore the potential of targeted physical activity interventions in sustaining PR benefits in COPD management, highlighting the need for further research to optimize comprehensive care strategies for this patient population.

Source: sciencedirect.Com/science/article/pii/S2531043724000473





Comments

Post a Comment

Popular posts from this blog

Co-authors of Minnesota State Fair history book optimistic for event's return - KSTP

Image
Co-authors of Minnesota State Fair history book optimistic for event&#039;s return - KSTP Co-authors of Minnesota State Fair history book optimistic for event&#039;s return - KSTP Posted: 02 May 2021 05:03 PM PDT "I do remember the polio pandemic. I was 8 years old at the time that that fair was canceled," Kathryn Koutsky said. "And my parents and I, we always went to the fair, and so that really affected me." And last year's modified drive-thru fair looked nothing like what's seen in the history books.  "The fair is so crowded that you just couldn't imagine going into the crowd. I mean, it was awfully sad," said Kathryn's daughter, Linda. "I loved going to the fair. I go several days each year, but you just knew there was no way we could go." But there is some hope for the state fair this year. On Friday, Gov. Tim Walz indicated Minnesota is on track for its retu
Read more

poliomyelitis treatment

Image
poliomyelitis treatment Drug and Device News March 2019 - P&T Community Posted: 04 Mar 2019 10:35 AM PST NEW DRUG APPROVALS Ontruzant, a Herceptin Biosimilar The FDA has approved trastuzumabdttb (Ontruzant, Samsung Bioepis Company, Ltd.) for HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Trastuzumabdttb, a HER2/neu receptor antagonist, is the third FDA-approved biosimilar of Herceptin (Genentech). Patients should be selected for therapy based on an FDA-approved companion diagnostic. Trastuzumab-dttb carries a boxed warning about the risks of cardiomyopathy, serious and fatal infusion reactions, embryo-fetal toxicity, and pulmonary toxicity. Ontruzant will be marketed and distributed in the U.S. by Merck. Sources: Samsung Bioepis, January 21, 2019; Ontruzant . prescribing information, January 2019; FDA, January 18, 2019 Vaxelis, a Combination Vaccine T
Read more

Polio was nearly extinct. Then the anti-vaxx movement reached Pakistan - Los Angeles Times

Image
Polio was nearly extinct. Then the anti-vaxx movement reached Pakistan - Los Angeles Times Polio was nearly extinct. Then the anti-vaxx movement reached Pakistan - Los Angeles Times Posted: 05 Sep 2019 12:00 AM PDT An anti-vaccination movement rooted in suspicions of modern medicine. Unsubstantiated rumors fueled by social media. Children infected with a disease that had been all but wiped out. Polio is making a troubling comeback in Pakistan, and it is being driven by some of the same forces spreading measles in the United States . Two years after health officials declared they were on the verge of eradicating the crippling childhood disease from Pakistan, one of the last countries where it remains endemic, at least 58 children here have tested positive for the virus since January. That is nearly five times the total of all of last year, and the most in a calendar year since 2014 — a major setback for a $1-billion-a-year global eradicat
Read more